knowledge -WSS

knowledge

author：Wikipedia 2025-09-07 14:07:37 - browse：1562

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Problems with a popular proposal to regulate AI in health care

explore

WSS

Focused ultrasound for uterine fibroids: an uphill battle

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Devoted Health’s losses in Medicare Advantage persist

What will save rural psychiatry services? Higher Medicaid payments

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Childbirth

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Devoted Health’s losses in Medicare Advantage persist

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Psychedelics group wrestles with new pharma identity

What will save rural psychiatry services? Higher Medicaid payments

Guidelines to prevent youth baseball injuries need more muscle

Adam's Biotech Scorecard: Do Sarepta's exon

Affirmative action in medical school literally saved lives

Dark money group runs ads on China biotech bill

Wikipedia

A protest over insulin prices is seen as a fight for life

Global cancer cases to surge 77% by 2050, WHO report says

Updated Covid vaccine has 54% effectiveness, new study suggests

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Adopting new red light myopia treatments may be short

Antibiotic resistance nearly killed me, so I'm raising awareness of it

explore

explore

hotspot

explore